Trial Profile
A randomized controlled trial of endostatin combined with single-agent gemcitabine in the first-line treatment of the elderly patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2016
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Jan 2016 New trial record